Urologic Oncology-Seminars and Original Investigations

Article	Citations
Urinary biomarkers in bladder cancer: A review of the current landscape and future directions	117
Papillary renal cell carcinoma: Review	45
Investigating the association between the urinary microbiome and bladder cancer: An exploratory study	41
Non-muscle-invasive bladder cancer: An overview of potential new treatment options	38
Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy	37
Phase I trial of docetaxel plus lutetium-177-labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 (177Lu‐J591) for metastatic castration‐resistant prostate cancer	30
Bacillus Calmette-Guerin (BCG): Its fight against pathogens and cancer	30
Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer	28
Differential efficacy of ablation therapy versus partial nephrectomy between clinical T1a and T1b renal tumors: A systematic review and meta-analysis	27
Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinoma	26
Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients	26
Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer	25
Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer	25
Oncological outcomes of salvage radical prostatectomy for recurrent prostate cancer in the contemporary era: A multicenter retrospective study	25
Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis	25
Development of robust artificial neural networks for prediction of 5-year survival in bladder cancer	25
PI-RADS 3 lesions: Does the association of the lesion volume with the prostate-specific antigen density matter in the diagnosis of clinically significant prostate cancer?	24
A national cross-sectional survey of financial toxicity among bladder cancer patients	23
Clinical utility of PSAD combined with PI-RADS category for the detection of clinically significant prostate cancer	23
Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder	23
Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer	23
Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer	23
Repurposing metformin as anticancer drug: Randomized controlled trial in advanced prostate cancer (MANSMED)	22
Telemedicine in management of genitourinary malignancies: Patient and physician perspectives	22
Mutational landscape of non-muscle-invasive bladder cancer	21

BCG infection (BCGitis) following intravesical instillation for bladder cancer and time interval between treatment and presentation: A systematic review	21
Diagnostic performance of the Bladder EpiCheck methylation test and photodynamic diagnosis-guided cystoscopy in the surveillance of high-risk non-muscle invasive bladder cancer: A single centre, prosp	21
Serum and urine biomarkers for detecting clinically significant prostate cancer	21
Pseudouridine as a novel biomarker in prostate cancer	21
Toward noninvasive follow-up of low-risk bladder cancer – Rationale and concept of the UroFollow trial*	20
A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02	20
Molecular tumor heterogeneity in muscle invasive bladder cancer: Biomarkers, subtypes, and implications for therapy	20
Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus	20
Anxiety, depression and urological cancer outcomes: A systematic review	19
Association of heavy metals and trace elements in renal cell carcinoma: A case-controlled study	19
Impact of the controlling nutritional status (CONUT) score on perioperative morbidity and oncological outcomes in patients with bladder cancer treated with radical cystectomy	18
The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparison	18
Prognostic value of preoperative albumin-to-fibrinogen ratio (AFR) in patients with bladder cancer treated with radical cystectomy	18
Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors	17
Clinical value of 18FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer	17
Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: A review	17
Pro-inflammatory cytokines and chemokines initiate multiple prostate cancer biologic pathways of cellular proliferation, heterogeneity and metastasis in a racially diverse population and underlie the	17
Fibroblast growth factor receptor: A systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma	17
Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era	17
Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma	17
Oncofid-P-B: a novel treatment for BCG unresponsive carcinoma in situ (CIS) of the bladder: Results of a prospective European Multicentre study at 15 months from treatment start	17
Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review	17
Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center	17
Referral pattern for urologic malignancies before and during the COVID-19 pandemic	16
Real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States	16
Artificial intelligence in urological oncology: An update and future applications	16
Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab	16
Prospective Validation of Clinical Usefulness of a Novel mRNA-based Urine Test (Xpert® Bladder Cancer Monitor) for surveillance in Non Muscle Invasive Bladder Cancer	16
Clinicopathological significance and prognostic value of cancer-associated fibroblasts in prostate cancer patients	16
Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BC	16
Does neoadjuvant chemotherapy have therapeutic benefit for node-positive upper tract urothelial carcinoma? Results of a multi-center cohort study	16
Can preoperative renal mass biopsy change clinical practice and reduce surgical intervention for small renal masses?	16
The role of Tc-99m MIBI scintigraphy in clinical T1 renal mass assessment: Does it have a real benefit?	15
Functional and oncological outcome of percutaneous cryoablation versus laparoscopic partial nephrectomy for clinical T1 renal tumors: A propensity score-matched analysis	15
Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis	15
Quality of life and adverse events in patients with nonmuscle invasive bladder cancer receiving adjuvant treatment with BCG, MMC, or chemohyperthermia	15
The stanford prostate cancer calculator: Development and external validation of online nomograms incorporating PIRADS scores to predict clinically significant prostate cancer	14
Inguinal lymph node dissection in the era of minimally invasive surgical technology	14
Prognostic nutritional index and prognosis in renal cell carcinoma: A systematic review and meta-analysis	14
Robotic-assisted tumor enucleation versus standard margin partial nephrectomy: Perioperative, renal functional, and oncologic outcomes for low and intermediate complexity renal masses	14
Contemporary trends in percutaneous renal mass biopsy utilization in the United States	14
Second line salvage systemic therapy for advanced penile cancer	14
Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma	14
Multicenter transperineal MRI-TRUS fusion guided outpatient clinic prostate biopsies under local anesthesia	14
Single center retrospective analysis of fifty-two prostate cancer patients with customized MR-guided transurethral ultrasound ablation (TULSA)	13
The robotic approach improves the outcomes of ERAS protocol after radical cystectomy: A prospective case-control analysis	13
Diagnostic accuracy of vesical imaging-reporting and data system (VI-RADS) in suspected muscle invasive bladder cancer: A systematic review and diagnostic meta-analysis	13
The use of 29 MHz transrectal micro-ultrasound to stratify the prostate cancer risk in patients with PI-RADS III lesions at multiparametric MRI: A single institutional analysis	13
Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma	13
Impact of preoperative systemic immune-inflammation Index on oncologic outcomes in bladder cancer patients treated with radical cystectomy	13

C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab	13
Decision regret, adverse outcomes, and treatment choice in men with localized prostate cancer: Results from a multi-site randomized trial	13
The effect of metastasectomy on overall survival in metastatic renal cell carcinoma: A systematic review and meta-analysis	13
Management of urologic cancers during the pandemic and potential impact of treatment deferrals on outcomes	13
A prognostic immune predictor, HLA-DRA, plays diverse roles in non-muscle invasive and muscle invasive bladder cancer	13
A 25 year perspective on the evolution and advances in an understanding of the biology, evaluation and treatment of kidney cancer	13
Implementation of a nonopioid protocol following robot-assisted radical cystectomy with intracorporeal urinary diversion	13
“Collecting duct carcinoma of the kidney: diagnosis and implications for management”	12
Robotic-Assisted Video-Endoscopic Inguinal Lymphadenectomy (RAVEIL) and Video-Endoscopic Inguinal Lymphadenectomy (VEIL) versus Open Inguinal Lymph-Node Dissection (OILND) in carcinoma of penis: Compa	12
Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high–grade non-muscle-invasive urothelial bladder cancer	12
Bladder cancer is associated with decreased urinary microbiota diversity and alterations in microbial community composition	12
Safety and side effects of transperineal prostate biopsy without antibiotic prophylaxis	12
New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer – What do we understand so far?	12
The combination cytology/epichek test in non muscle invasive bladder carcinoma follow-up: Effective tool or useless expence?	12
Metastasis-directed radiation therapy after radical cystectomy for bladder cancer	12
Comprehensive genomic profiling of metastatic collecting duct carcinoma, renal medullary carcinoma, and clear cell renal cell carcinoma	12
A novel nomogram predicting lymph node invasion among patients with prostate cancer: The importance of extracapsular extension at multiparametric magnetic resonance imaging	12
Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non–muscle-invasive bladder cancer after BCG failure	11
Disparities in precision medicine—Examining germline genetic counseling and testing patterns among men with prostate cancer	11
Interpreting nephrometry scores with three-dimensional virtual modelling for better planning of robotic partial nephrectomy and predicting complications	11
Assessing patient risk from cancer and COVID-19: Managing patient distress	11
Impact of systemic Immune–inflammation Index on oncologic outcomes in patients treated with radical prostatectomy for clinically nonmetastatic prostate cancer	11
A machine learning approach to predict progression on active surveillance for prostate cancer	11
Comparison of renal function after open radical cystectomy, extracorporeal robot assisted radical cystectomy, and intracorporeal robot assisted radical cystectomy	11
Evolving insights into penile cancer pathology and the eighth edition of the AJCC TNM staging system	11
The utility of intraoperative contrast-enhanced ultrasound in detecting residual disease after focal HIFU for localized prostate cancer	11
The role of multiparametric MRI in active surveillance for low-risk prostate cancer: The ROMAS randomized controlled trial	11
The bladder epicheck test and cytology in the follow-up of patients with non-muscle-invasive high grade bladder carcinoma.	11
Utilization of renal mass biopsy in patients with localized renal cell carcinoma: A population-based study utilizing the National Cancer Database	11
Nephroureterectomy vs. segmental ureterectomy of clinically localized, high-grade, urothelial carcinoma of the ureter: Practice patterns and outcomes	11
Long term outcomes of ureteroscopic management of upper tract urothelial carcinoma	11
Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer	11
The impact of lymphovascular invasion in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma: An extensive updated systematic review and meta-analysis	11
Renal cell carcinoma with tumor thrombus: A review of relevant anatomy and surgical techniques for the general urologist	11
A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy	11
Combination MRI-targeted and systematic prostate biopsy may overestimate gleason grade on final surgical pathology and impact risk stratification	11
Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for 18F-fluciclovine-PET/CT in delineating sites of recurrence and identifying patients with oligometasta	11
Age and gleason score upgrading between prostate biopsy and radical prostatectomy: Is this still true in the multiparametric resonance imaging era?	11
Effect of frailty and comorbidity on surgical contraindication in patients with localized prostate cancer (FRART-PC Study)	11
Organ preserving radiation strategies for penile cancer	10
Post-translational modifications in bladder cancer: Expanding the tumor target repertoire	10
Postoperative membranous urethral length is the single most important surgical factor predicting recovery of postoperative urinary continence	10
Estimating the rate and reasons of clinical trial failure in urologic oncology	10
Trends in palliative care interventions among patients with advanced bladder, prostate, or kidney cancer: A retrospective cohort study	10
The role of 18F-FDG PET/CT scan compared to CT-scan alone for lymph node staging before radical cystectomy in patients with bladder cancer	10
How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series	10
Prognostic value of circulating tumor cells and immune-inflammatory cells in patients with renal cell carcinoma	10
An evaluation of trends in the representation of patients by age, sex, and diverse race/ethnic groups in bladder and kidney cancer clinical trials	10
Artificial intelligence in prostate cancer: Definitions, current research, and future directions	10
Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction cours	10
MMPs, tyrosine kinase signaling and extracellular matrix proteolysis in kidney cancer	10
Characterization of tumor thrombus in renal cell carcinoma with prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT)	10
Locoregional recurrence after cystectomy in muscle invasive bladder cancer: Implications for adjuvant radiotherapy	10
External validation of the VENUSS prognostic model to predict recurrence after surgery in non-metastatic papillary renal cell carcinoma: A multi-institutional analysis	10
Cachexia index in predicting outcomes among patients receiving immune checkpoint inhibitor treatment for metastatic renal cell carcinoma	10
Polymorphisms in androgen metabolism genes with serum testosterone levels and prognosis in androgen-deprivation therapy	10
Utility of PSA density in patients with PI-RADS 3 lesions across a large multi-institutional collaborative	10
Limitations of overlapping cores in systematic and MRI-US fusion biopsy	10
Emergence of triplet therapy for metastatic castration-sensitive prostate cancer: An updated systematic review and network meta-analysis	10
Free-indocyanine green-guided pelvic lymph node dissection during radical prostatectomy	10
Do patients with a PI-RADS 5 lesion identified on magnetic resonance imaging require systematic biopsy in addition to targeted biopsy?	10
Critical shortage in BCG immunotherapy: How did we get here and where will it take us?	10
The role of perilesional and multiparametric resonance imaging-targeted biopsies to reduce the risk of upgrading at radical prostatectomy pathology: A retrospective monocentric study	9
Predictors of survival, healthcare resource utilization, and healthcare costs in veterans with non-metastatic castration-resistant prostate cancer	9
Evaluation of post-ablation mpMRI as a predictor of residual prostate cancer after focal high intensity focused ultrasound (HIFU) ablation	9
Plasmacytoid urothelial carcinoma of the bladder: MRI features and their association with survival	9
Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer	9
Real-world use of systemic therapies in men with metastatic castration resistant prostate cancer (mCRPC) in Canada	9
Multidisciplinary Approach for the Management of Penoscrotal Extramammary Paget's disease –An eUROGEN study	9
Incidence, risk factors and outcomes of urethral recurrence after radical cystectomy for bladder cancer: A systematic review and meta-analysis	9
Long term outcomes for patients with von Hippel-Lindau and Pheochromocytoma: defining the role of active surveillance	9
Outcomes of palliative cystectomy in patients with locally advanced pT4 bladder cancer	9
Histone-dependent PARP-1 inhibitors: A novel therapeutic modality for the treatment of prostate and renal cancers	9
Management of prostate cancer after holmium laser enucleation of the prostate	9
Systemic therapy in bladder preservation	9
TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer	9
Baseline basophil and basophil-to-lymphocyte status is associated with clinical outcomes in metastatic hormone sensitive prostate cancer	9
Comparison of the prognosis of primary vs. progressive muscle invasive bladder cancer after radical cystectomy: Results from a large multicenter study	9
Association of Bacillus Calmette–Guerin shortages with bladder cancer recurrence: A single-center retrospective study	9
[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab	9

Comprehensive genomic profiling of histologic subtypes of urethral carcinomas	9
Outcomes of perineal urethrostomy for penile cancer: A 20-year international multicenter experience	9
The effect of race on stage at presentation and survival in upper tract urothelial carcinoma	9
Pathological findings at radical prostatectomy of biopsy naïve men diagnosed with MRI targeted biopsy alone without concomitant standard systematic sampling	9
Survival trends in chemotherapy exposed metastatic bladder cancer patients and chemotherapy effect across different age, sex, and race/ethnicity	9
Primary Ta high grade bladder tumors: Determination of the risk of progression	9
Management of penile cancer patients during the COVID-19 pandemic: An eUROGEN accelerated Delphi consensus study	9
Management of bone and metabolic effects of androgen deprivation therapy	8
Defining radical cystectomy using the ICD-10 procedure coding system	8
Characterizing molecular subtypes of high-risk non-muscle-invasive bladder cancer in African American patients	8
Practice patterns for extended venous thromboembolism chemoprophylaxis among urologic oncologists after radical cystectomy	8
Risk of renal cancer in patients with inflammatory bowel disease: A pooled analysis of population-based studies	8
Prognostic significance of extent of venous tumor thrombus in patients with non-metastatic renal cell carcinoma: Results from a Canadian multi-institutional collaborative	8
Post-traumatic stress disorder symptoms in non-muscle-invasive bladder cancer survivors: A population-based study	8
Integrating radiomics with the vesical imaging-reporting and data system to predict muscle invasion of bladder cancer	8
Effectiveness and safety of adjuvant chemotherapy compared to neoadjuvant chemotherapy in patients with penile cancer and positive lymph nodes regarding overall survival and free disease survival: a s	8
Exploring the opportunities and challenges of implementing artificial intelligence in healthcare: A systematic literature review	8
Predicting morbidity and mortality after radical cystectomy using risk calculators: A comprehensive review of the literature	8
Barriers to sexual recovery in men with prostate, bladder and colorectal cancer	8
Bladder cancer risk stratification using a urinary mRNA biomarker panel – A path towards cystoscopy triaging	8
Benefit of lymph node dissection in cN+ patients in the treatment of upper tract urothelial carcinoma: Analysis of NCDB registry	8
The impact of time to prostate specific antigen nadir on biochemical recurrence and mortality rates after radiation therapy for localized prostate cancer	8
The association of salvage intravesical therapy following BCG with pathologic outcomes and survival after radical cystectomy for patients with high-grade non-muscle invasive bladder cancer: A multi-in	8
Real-world treatment patterns and clinical outcomes with first-line therapy in patients with locally advanced/metastatic urothelial carcinoma by cisplatin-eligibility	8
Clinical and pathological features of renal epithelioid angiomyolipoma (PEComa): A single institution series	8
Management of male sexual dysfunction after cancer treatment	8
A retrospective study on optimal number of cycles of the first-line platinum-based chemotherapy for metastatic urothelial carcinoma	8
Mechanisms and markers of resistance to androgen signaling inhibitors in patients with metastatic castration-resistant prostate cancer	8
External validation of the Briganti nomogram predicting lymph node invasion in patients with intermediate and high-risk prostate cancer diagnosed with magnetic resonance imaging-targeted and systemati	8
Focal brachytherapy for localized prostate cancer: 5.7-year clinical outcomes and a pair-matched study with radical prostatectomy	8
Oncologic outcomes of laparoscopic radical nephroureterectomy in conjunction with template-based lymph node dissection: An extended follow-up study	8
The effect of race/ethnicity on active treatment rates among septuagenarian or older low risk prostate cancer patients	8
Clinical trial of high dose hyperthermic intravesical mitomycin C for intermediate and high-risk non–muscle invasive bladder cancer during BCG shortage	8
Optimizing MRI-targeted prostate biopsy: the diagnostic benefit of additional targeted biopsy cores	8
Prognostic value of the fluctuation in the neutrophil–lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma	8
Race, ethnicity, and gender reporting in North American clinical trials for BCG-unresponsive non-muscle invasive bladder cancer	8
Long-term outcomes of incidental prostate cancer at radical cystectomy	8
Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors	8
Phase II multi-center trial of optical coherence tomography as an adjunct to white light cystoscopy for intravesical real time imaging and staging of bladder cancer	8
Catalog of prognostic tissue-based biomarkers in patients treated with neoadjuvant systemic therapy for urothelial carcinoma of the bladder: a systematic review	8
Applicant perceptions of virtual interviews for society of urologic oncology fellowships during the COVID-19 pandemic	8
Clinicopathological characteristics, prognosis, and chemosensitivity in patients with metastatic upper tract urothelial carcinoma	8
Optimizing androgen deprivation therapy with radiation therapy for aggressive localized and locally advanced prostate cancer	8
Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy?	8
Differential contribution of the factors determining long-term renal function after partial nephrectomy over time	8
Antibody-drug conjugates for urothelial carcinoma	8
Is partial nephrectomy safe and effective in the setting of frail comorbid patients affected by renal cell carcinoma? Insights from the RECORD 2 multicentre prospective study	8
Can repeat biopsy be skipped after initial complete resection of T1 bladder cancer? The role of a novel urinary mRNA biomarker	8
“Real-world” outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma	8
Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer	7
Validation of the European association of urology biochemical recurrence risk groups after radical prostatectomy in an Asian cohort and suggestions for refinement	7
The effect of tumor grade heterogeneity on recurrence in non-muscle invasive bladder cancer	7
Out-of-pocket costs for commercially insured patients with localized prostate cancer	7
Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study	7
Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand?	7
Impact of CoVID-19 on resident and fellow education: Current guidance and future opportunities for urologic oncology training programs	7
Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray project	7
Collecting duct carcinoma: A single‐institution retrospective study	7
The impact of health literacy on urologic oncology care	7
Survival benefit of chemotherapy in a contemporary cohort of metastatic urachal carcinoma	7
Primary lymph-node staging with 68Ga-PSMA PET in high-risk prostate cancer: pathologic correlation with extended pelvic lymphadenectomy specimens	7
Development of novel ACN (albumin, C-reactive protein and neutrophil-to-lymphocyte ratio) prognostication model for patients with metastatic renal cell carcinoma receiving first-line molecular-targete	7
Real-world burden of illness and unmet need in locally advanced or metastatic urothelial carcinoma following discontinuation of PD-1/L1 inhibitor therapy: A Medicare claims database analysis	7
Survival and oncologic outcomes of complete transurethral resection of bladder tumor prior to neoadjuvant chemotherapy for muscle-invasive bladder cancer	7
Medium Term Outcomes of Focal Cryoablation for Intermediate and High Risk Prostate Cancer: MRI and PSA are Not Predictive of Residual or Recurrent Disease	7
Emerging promising biomarkers for treatment decision in metastatic castration-resistant prostate cancer	7
Site of metastatic recurrence impacts prognosis in patients with high-grade upper tract urothelial carcinoma	7
Financial incentives and wearable activity monitors to increase ambulation after cystectomy: A randomized controlled trial	7
Immune checkpoints inhibitors in the management of high-risk non-muscle-invasive bladder cancer. A scoping review	7
Role of circulating tumor cells in patients with metastatic clear-cell renal cell carcinoma	7
Diagnostic performance and predictive capacity of early urine cytology after transurethral resection of nonmuscle invasive bladder cancer: A prospective study	7
Efficacy of nivolumab plus ipilimumab as first-line therapy for primary tumors in patients with renal cell carcinoma	7
Comparative study of postoperative complications after radical cystectomy during the past two decades in Japan: Radical cystectomy remains associated with significant postoperative morbidities	7
Impact of preoperative serum albumin-globulin ratio on disease outcome after radical cystectomy for urothelial carcinoma of the bladder	7
Statin use and risk of prostate cancer biochemical recurrence after radical prostatectomy	7
Obesity is associated with adverse short-term perioperative outcomes in patients treated with open and robot-assisted radical cystectomy for bladder cancer	7
The systemic inflammation response index: An independent predictive factor for survival outcomes of bladder cancer stronger than other inflammatory markers	7
Patient reported outcomes and health related quality of life in localized prostate cancer: A review of current evidence	7
The effect of number of treatment cycles of platinum-based first-line chemotherapy on maximum radiological response in patients with advanced urothelial carcinoma	7
Prognostic Value of Sarcopenia and Albumin in the Surgical Management of Localized Renal Cell Carcinoma	7
Sensitivity of multiparametric MRI and targeted biopsy for detection of adverse pathologies (Cribriform gleason pattern 4 and intraductal carcinoma): Correlation of detected and missed prostate cancer	7
Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors	7
Plasmacytoid urothelial carcinoma (UC) are luminal tumors with similar CD8+ Tcell density and PD-L1 protein expression on immune cells as compared to conventional UC	7
Trends in urologic oncology clinical practice and medical education under COVID-19 pandemic: An international survey of senior clinical and academic urologists	7
The additive value of mpMRI on prostate cancer detection: Comparison between patients with and without a suspicious digital rectal examination (DRE)	7
The prognostic and clinicopathological significance of Tim-3 and PD-1 expression in the prognosis of upper urinary tract urothelial carcinoma	7
Epigenetics regulation of prostate cancer: Biomarker and therapeutic potential	7
The association of phosphodiesterase-5 inhibitors with the biochemical recurrence-free and overall survival of patients with prostate cancer following radical prostatectomy	7
Can anesthetics affect bladder cancer recurrence? Total intravenous versus volatile anesthesia in patients undergoing robot-assisted radical cystectomy: A single institution retrospective analysis	7
The effect of sex on disease stage and survival after radical cystectomy: a population-based analysis	7
PSMA PET predicts metastasis-free survival in the setting of salvage radiotherapy after radical prostatectomy	7
Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey	6
Inverted urethral flap reconstruction after partial penectomy: Long-term oncological and functional outcomes	6
Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients	6
The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy	6